Welcome to our dedicated page for CYAD news (Ticker: CYAD), a resource for investors and traders seeking the latest updates and insights on CYAD stock.
Celyad Oncology reports corporate, financial, and regulatory news as a biotechnology company focused primarily on unlocking the potential of its intellectual property. Company updates commonly address efforts to partner or out-license selected technologies, asset divestitures such as research-facility equipment and the C-CATHez catheter, and financial results that discuss operating expenses, cash resources, and capital needs.
News releases also cover Belgian transparency notifications, major shareholding thresholds, total voting rights, share counts, double voting rights, and warrants tied to the company’s Euronext-listed securities.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that as of May 25, 2022, 350 registered shares will benefit from double voting rights. This change increases the total number of voting rights to 24,962,331. The company disclosed this in compliance with Belgian regulations regarding major shareholdings. Key figures include a total share capital of €78,584,224.33, with 20,225,581 shares having single voting rights and 2,368,375 shares having double voting rights.
Celyad Oncology SA (Brussels:CYAD) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company will present virtually, with on-demand access starting at 7:00 a.m. EST on May 24, 2022. Celyad Oncology focuses on developing CAR T therapies for cancer, including both allogeneic and autologous candidates targeting hematological malignancies and solid tumors. The company, founded in 2007, received funding from the Walloon Region of Belgium to support its programs.
The financial update from Celyad Oncology (CYAD) highlights a cash position of €20.5 million ($22.9 million) and a net cash burn of €9.5 million ($10.6 million) for Q1 2022. The Phase 1 IMMUNICY-1 trial for CYAD-211 continues to enroll patients to evaluate its effectiveness against relapsed/refractory multiple myeloma. However, the CYAD-101-002 Phase 1b trial remains on clinical hold due to safety concerns, following reported fatalities. The company plans to release additional data on CYAD-211 in H2 2022 and expects its cash reserves to last until mid-2023.
Summary not available.
Celyad Oncology SA (NASDAQ: CYAD) provided an update on its business and financial results for Q1 2022. The Phase 1 IMMUNICY-1 trial for the allogeneic CAR T candidate CYAD-211 for relapsed/refractory multiple myeloma (MM) is ongoing, with additional data expected in H2 2022. However, the CYAD-101-002 Phase 1b trial remains on clinical hold after two fatalities were reported. As of March 31, 2022, the company had €20.6 million in cash, with a net cash burn of €9.4 million during the quarter, sufficient to fund operations until mid-2023.
Celyad Oncology (CYAD) reported its 2021 results, showing a net loss of €26.5 million or €1.70 per share, a significant increase from €17.2 million or €1.23 per share in 2020. The company had cash and equivalents of €30 million as of Dec 31, 2021, expected to fund operations until mid-2023. Clinical updates included encouraging results from the Phase 1 IMMUNICY-1 trial of CYAD-211 for relapsed/refractory multiple myeloma, while the CYAD-101 Phase 1b trial is on clinical hold. The firm anticipates upcoming data releases and IND submissions in 2022.
Celyad Oncology (Euronext & Nasdaq: CYAD) announced it will report its full year 2021 financial and operational results on March 24. Following the results, management will host a conference call on March 25 at 1 p.m. CET to discuss the outcomes and provide updates on recent progress and milestones. Celyad specializes in the development of CAR T cell therapies for cancer treatment, focusing on both allogeneic and autologous therapies to address various malignancies.
Celyad Oncology SA (Euronext & Nasdaq: CYAD) announced that the U.S. FDA placed a clinical hold on its CYAD-101-002 (KEYNOTE-B79) Phase 1b trial on March 1, 2022, due to insufficient risk assessment data. This decision follows the company's voluntary pause of the trial on February 28, 2022, after reports of two fatalities. Celyad specializes in CAR T cell therapies for cancer treatment, focusing on both allogeneic and autologous candidates.
Celyad Oncology SA (CYAD) has announced a voluntary pause of the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial due to reports of two fatalities with similar pulmonary issues. This trial investigates the CYAD-101 therapy, designed for patients with refractory metastatic colorectal cancer. The company prioritizes patient safety and is investigating these serious incidents while keeping regulatory bodies informed. Previous trials with CYAD-101 showed no dose-limiting toxicities. Celyad anticipates no impact on its other candidates, including CYAD-211 for multiple myeloma.
Celyad Oncology announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference from February 14 to 18, 2022, with a presentation scheduled for February 18 at 8 a.m. ET by CEO Filippo Petti. The company focuses on developing chimeric antigen receptor T cell (CAR T) therapies for cancer, including both allogeneic and autologous treatments for hematological malignancies and solid tumors. Celyad has received funding from the Walloon Region of Belgium to support its CAR T programs.